home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2781.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
41 lines
Document 2781
DOCN M94A2781
TI Passive immunotherapy in AIDS: results of a double blind randomised
study. French Passive Immunotherapy Study Group.
DT 9412
AU Lefrere JJ; Vittecoq D; INTS, hop. St-Antoine, Paris.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):226 (abstract no. PB0335). Unique
Identifier : AIDSLINE ICA10/94369794
AB A randomized double-blind controlled trial was conducted to determine
the long term efficacy of passive immunotherapy (PI) in the treatment of
symptomatic HIV infection. This prospective trial (IPOO2) included
symptomatic patients randomized in 2 groups. One group received plasma
rich in anti-p24 antibody (HIV+P), the other received standard
seronegative plasma (HIV- P). Each patient in both groups received a 300
mL infusion every 14 days over a one-year period, in addition to
zidovudine and other prophylactic treatments. To obtain HIV+P, donors
were selected among symptomless anti-HIV+ individuals with a CD4 count >
or = 400 and a high concentration of anti-p24 antibody. The plasmas were
heated before infusion. Upon the advice of the independent committee,
the inclusion of new patients ceased in July 1993. At this time, 86
patients had been included. A significant difference was observed
between both groups in the delay of appearance of the onset of the first
AIDS defining event (p < 0.009) and in the cumulative number of events
(p < 0.0008) over the study period of one-year; 18 deaths occurred
within the study period, 7 in the treated group and 11 in the controls
(p = .27). The number of days of hospitalisation was 679 in the treated
group and 1379 in the control group. Infusions of HIV+P every two weeks
may favorably modulate the natural history of infection and improve the
quality of life of AIDS patients.
DE Acquired Immunodeficiency Syndrome/MORTALITY/PREVENTION & CONTROL
AIDS-Related Opportunistic Infections/PREVENTION & CONTROL Combined
Modality Therapy Comparative Study Double-Blind Method Human HIV
Antibodies/IMMUNOLOGY/*THERAPEUTIC USE HIV Core Protein p24/*IMMUNOLOGY
HIV Infections/DRUG THERAPY/*THERAPY HIV-1/*IMMUNOLOGY *Immunization,
Passive Prospective Studies Treatment Outcome Zidovudine/THERAPEUTIC
USE CLINICAL TRIAL MEETING ABSTRACT RANDOMIZED CONTROLLED TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).